Abstract
Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation. By inhibiting BRAF, vemurafenib prevents the mitogen-activated protein kinase (MAPK) pathway from driving melanoma growth. Here we present a patient with paradoxical activation of the MAPK pathway by vemurafenib, ultimately resulting in deleterious cutaneous manifestations. An emphasis on close follow-up is warranted for new or changing lesions for patients on this medication and other BRAF inhibitors.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Female
-
Humans
-
Indoles / adverse effects
-
Indoles / pharmacology
-
Indoles / therapeutic use*
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / pathology
-
Middle Aged
-
Mitogen-Activated Protein Kinases / metabolism
-
Neoplasm Metastasis
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Skin Neoplasms / pathology
-
Sulfonamides / adverse effects
-
Sulfonamides / pharmacology
-
Sulfonamides / therapeutic use*
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Indoles
-
Protein Kinase Inhibitors
-
Sulfonamides
-
Vemurafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Mitogen-Activated Protein Kinases